CSE:HAVN - Post Discussion
Post by
NLMoose on Jul 20, 2021 1:09pm
Another Disappointment With New Record Low
While Psychedelic Drugs are experiencing increasing demand, HAVN Life Sciences continues to suffer from mismanagement and dreaded shortsellers as their stock has now reached a new record low.
Perhaps a very strong management shakeup similar to FSD Pharma is needed.
Be the first to comment on this post